TSX Venture:
QPT
EDMONTON, AB, July 21,
2022 /CNW/ - Quest PharmaTech Inc. (TSXV: QPT)
("Quest" or the "Company") today announced the results of its
July 19, 2022 annual general meeting
of shareholders.
The Company is pleased to announce the following 4 directors
have been re-elected to the Company's Board of Directors:
J. Mark Lievonen, C.M., FCPA,
FCA, LLD
Jeffrey Shon, JD
Shawn Lu, CIM, MFin
Madi R. Madiyalakan, Ph.D.
At the meeting, shareholders reappointed the Company's auditors,
Kingston Ross Pasnak, LLP.
"We are pleased with the AGM results and wish to thank our
shareholders for their continuing support," said Dr. Madi R.
Madiyalakan, Chief Executive Officer for Quest. "I would also
like to thank our Board members for their continuing service.
I am confident that Quest's Board of Directors will be able to help
the Company execute its business strategy to add value to our
shareholders.
Approximately 77,757,170 shares were voted for the Company's
shareholder meeting representing approximately 46% of the Company's
shares eligible to vote.
On a corporate matter, Quest announces the granting of 1,300,000
stock options to Directors and Officers, all at a volume weighted
average exercise price of $0.09 per
common share, expiring 10 years from the date of grant, subject to
TSX Venture Exchange approval.
About Quest PharmaTech Inc.
Quest PharmaTech Inc is a publicly traded, Canadian based
biopharmaceutical company (TSX-V:QPT) developing products to
improve the quality of life. The company has a 42.5% ownership
interest in OncoQuest Inc. which sold its immunotherapy technology
to OncoQuest Pharmaceuticals, Inc. Quest also has an equity
interest in OncoVent, a Chinese joint venture developing
antibody-based immunotherapeutic products for cancer for the
Greater China territory. Quest has
an ownership interest in Bioceltran which is focused on SP
Technology™ for transdermal delivery of drugs and photosensitizers
for pharmaceutical and cosmetic purposes. Quest is also developing
an antibody licensed from University of
Nebraska, AR 9.6 mAb against truncated O-glycan on MUC16,
for targeted cancer therapy applications. To learn more,
visit www.questpharmatech.com
Forward Looking Statements
This press
release includes forward-looking statements. In some cases,
forward-looking statements can be identified by terminology such as
"may," "should," "potential," "continue," "expects," "anticipates,"
"intends," "plans," "believes," "estimates," and similar
expressions. These statements are based on management's
expectations and assumptions as of the date of this press release
and are subject to a number of risks and uncertainties, many of
which are difficult to predict that could cause actual results to
differ materially from current expectations and assumptions from
those set forth or implied by any forward-looking
statements. The information in this release is provided only
as of the date of this release and the company undertakes no
obligation to update any forward-looking statements contained in
this release based on new information, future events, or otherwise,
except as required by law.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE Quest PharmaTech Inc.